An Infusion Study for Patients with Newly Diagnosed Type 1 Diabetes
Purpose
This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.
People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.
Researchers hope this treatment will:
-
Help the body keep making some of its own insulin
-
Reduce the amount of insulin people need to take
-
Improve blood sugar control
-
Lower the risk of very low blood sugar levels
The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.
Could this study be right for you?
- Must be diagnosed with Type 1 Diabetes in the past 2 months
- Must have had a positive test for at least one Type 1 Diabetes antibody
- For female participants of childbearing potential - must use a contraception method (or abstinence)